Evolving Concepts in Post-PCI Antiplatelets Therapy
Indian Journal of Clinical Cardiology · 2020
DOI: 10.1177/2632463620953677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Clinical Cardiology, 2020. Verfasst von Kartik Pandurang Jadhav und 1 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The standard duration dual antiplatelet therapy (DAPT) is considered as gold standard for post percutaneous coronary intervention (PCI) medical therapy, as mentioned in American College of Cardiology/American Heart Association 2016 and European Society of Cardiology 2017 guidelines. Recently it has been challenged, in terms of duration and composition of this therapy. Many newer regimens and therapeutic drugs are being tried in large randomized clinical trial studies and found to be as effective as DAPT if not superior. There is general trend to introduce better antiplatelets like P2Y12 inhibitor (prasugrel and ticagrelor) as monotherapy for longer duration and restricting use of aspirin beyond 3 months. This review article helps us in understanding the evolution of DAPT therapy, formation of guidelines, and what are the new and evolving concepts in post-PCI medical therapy.
Zitieren
APA
Jadhav, K. P., & Jariwala, P. V. (2020). Evolving Concepts in Post-PCI Antiplatelets Therapy. Indian Journal of Clinical Cardiology. https://doi.org/10.1177/2632463620953677
Vancouver
Jadhav KP, Jariwala PV. Evolving Concepts in Post-PCI Antiplatelets Therapy. Indian Journal of Clinical Cardiology. 2020. doi:10.1177/2632463620953677
BibTeX
@article{Jadhav2020,
author = {Jadhav, Kartik Pandurang and Jariwala, Pankaj V.},
title = {Evolving Concepts in Post-PCI Antiplatelets Therapy},
journal = {Indian Journal of Clinical Cardiology},
year = {2020},
doi = {10.1177/2632463620953677}
}
EUVIMED